JP2009506044A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506044A5
JP2009506044A5 JP2008528086A JP2008528086A JP2009506044A5 JP 2009506044 A5 JP2009506044 A5 JP 2009506044A5 JP 2008528086 A JP2008528086 A JP 2008528086A JP 2008528086 A JP2008528086 A JP 2008528086A JP 2009506044 A5 JP2009506044 A5 JP 2009506044A5
Authority
JP
Japan
Prior art keywords
medicament
subject
rosehips
inflammatory response
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008528086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032847 external-priority patent/WO2007024901A1/en
Publication of JP2009506044A publication Critical patent/JP2009506044A/ja
Publication of JP2009506044A5 publication Critical patent/JP2009506044A5/ja
Pending legal-status Critical Current

Links

JP2008528086A 2005-08-23 2006-08-23 サイトカインの調節物質及び関連する使用方法 Pending JP2009506044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71073005P 2005-08-23 2005-08-23
PCT/US2006/032847 WO2007024901A1 (en) 2005-08-23 2006-08-23 Cytokine modulators and related methods of use

Publications (2)

Publication Number Publication Date
JP2009506044A JP2009506044A (ja) 2009-02-12
JP2009506044A5 true JP2009506044A5 (enExample) 2010-04-08

Family

ID=37575241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008528086A Pending JP2009506044A (ja) 2005-08-23 2006-08-23 サイトカインの調節物質及び関連する使用方法

Country Status (4)

Country Link
JP (1) JP2009506044A (enExample)
KR (1) KR20080041703A (enExample)
CN (1) CN101291681A (enExample)
WO (1) WO2007024901A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009030351A1 (de) * 2009-06-22 2010-12-23 Gelita Ag Zusammensetzung zur Behandlung von degenerativen Gelenkerkrankungen
KR101056129B1 (ko) * 2009-12-15 2011-08-11 주식회사 엘지생활건강 항염증용 조성물
EP2433629B1 (en) * 2010-09-22 2017-11-08 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Use of boswellic acids for the prophylaxis and/or treatment of damages and/or inflammation of the islets of Langerhans
CN102258191B (zh) * 2010-12-23 2012-12-19 天津天狮生物发展有限公司 预防慢性炎症的抗氧化保健食品及制备方法
ITMI20121570A1 (it) * 2012-09-20 2014-03-21 Indena Spa Nuovi estratti di cynara scolimus, coffea spp. e olea europaea per il trattamento della sindrome metabolica
KR101944113B1 (ko) * 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
TWI732147B (zh) * 2018-10-26 2021-07-01 臺北醫學大學 用於抑制乙醯膽鹼酯酶之萃取物及組合物
CN109907144A (zh) * 2019-04-19 2019-06-21 陕西科技大学 一种具有控制血糖功效的蓝莓荨麻茶及其制备方法
FR3096893B1 (fr) * 2019-06-06 2022-08-05 Laboratoire Exact Composition a base d’extrait de jeunes pousses et utilisation pour la prevention et le traitement des maladies liees au vieillissement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis
DE10153949A1 (de) * 2000-11-07 2002-08-01 Engelbert Grzeschik Verwendung von Beerensamenölen
WO2005025586A1 (en) * 2003-09-12 2005-03-24 Access Business Group International Llc Cytokine modulators and related method of use
AU2004273813A1 (en) * 2003-09-12 2005-03-31 Access Business Group International Llc Program for regulating health conditions
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods

Similar Documents

Publication Publication Date Title
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
HRP20240317T1 (hr) Liječenje hepatičke encefalopatije uporabom rifaksimina
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
MX348491B (es) Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
ECSP088239A (es) Composición de liberación de fármaco sostenida
JP2010527347A5 (enExample)
MX348054B (es) Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
JP2009538898A5 (enExample)
JP2010520246A5 (enExample)
PE20081301A1 (es) Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP2010525055A5 (enExample)
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
JP2009506044A5 (enExample)
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
JP2019089796A5 (enExample)
IL192611A0 (en) Biologically active composition comprising ethylcellulose
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
MX2010001243A (es) Composicion anti-inflamatoria.
JP2008518699A5 (enExample)
ECSP10010683A (es) Una formulacion farmacéutica sólida
JP2009516719A5 (enExample)